ON-TARGETplus Human SLC7A5 (8140) siRNA - Individual

Protocol tips

Upstream tips	Protocol tips	Downstream tips
	Non-targeting short interfering RNA (siRNA) (cat # D-001810-01-20), ON-TARGET plus human siRNA's against AHR (cat # J-004990-08-0010, and cat # J-004990-06-0010) and LAT1 (cat # J-004953-09-0010) were purchased from GE Dharmacon (Lafayette, CO). MDA-MB-231 BCCs were purchased from ATCC (Manassas, VA) and maintained in DMEM, 10% FBS, with penicillin (100 IU/mL) and streptomycin (100 IU/mL). The siRNA knockdowns were performed as detailed in our prior reports [33, 34]. Briefly, 200,000 cells (MDA-MB-231) in 1 mL of DMEM supplemented with 10% FBS were mixed directly with 100 nM of siRNA that was non-targeting, AHR-targeting or LAT1-targeting and 3 μL of Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) and immediately plated in 35 mm tissue culture plates for 48 hrs.

Protocol tips

Non-targeting short interfering RNA (siRNA) (cat # D-001810-01-20), ON-TARGET plus human siRNA's against AHR (cat # J-004990-08-0010, and cat # J-004990-06-0010) and LAT1 (cat # J-004953-09-0010) were purchased from GE Dharmacon (Lafayette, CO). MDA-MB-231 BCCs were purchased from ATCC (Manassas, VA) and maintained in DMEM, 10% FBS, with penicillin (100 IU/mL) and streptomycin (100 IU/mL). The siRNA knockdowns were performed as detailed in our prior reports [33, 34]. Briefly, 200,000 cells (MDA-MB-231) in 1 mL of DMEM supplemented with 10% FBS were mixed directly with 100 nM of siRNA that was non-targeting, AHR-targeting or LAT1-targeting and 3 μL of Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) and immediately plated in 35 mm tissue culture plates for 48 hrs.

Publication protocol

Non-targeting short interfering RNA (siRNA) (cat # D-001810-01-20), ON-TARGET plus human siRNA's against AHR (cat # J-004990-08-0010, and cat # J-004990-06-0010) and LAT1 (cat # J-004953-09-0010) were purchased from GE Dharmacon (Lafayette, CO). MDA-MB-231 BCCs were purchased from ATCC (Manassas, VA) and maintained in DMEM, 10% FBS, with penicillin (100 IU/mL) and streptomycin (100 IU/mL). The siRNA knockdowns were performed as detailed in our prior reports [33, 34]. Briefly, 200,000 cells (MDA-MB-231) in 1 mL of DMEM supplemented with 10% FBS were mixed directly with 100 nM of siRNA that was non-targeting, AHR-targeting or LAT1-targeting and 3 μL of Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) and immediately plated in 35 mm tissue culture plates for 48 hrs.

Full paper   Login or join for free to view the full paper.

Reviews

Discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing siRNA / miRNA gene silencing Human - MDA-MB-231 LAT1/SLC7A5 using ON-TARGETplus Human SLC7A5 (8140) siRNA - Individual from Horizon Discovery Ltd..

Manufacturer protocol

Download the product protocol from Horizon Discovery Ltd. for ON-TARGETplus Human SLC7A5 (8140) siRNA - Individual below.

Download manufacturer protocol

Videos

Check out videos that might be relevant for performing siRNA / miRNA gene silencing Human - MDA-MB-231 LAT1/SLC7A5 using ON-TARGETplus Human SLC7A5 (8140) siRNA - Individual from Horizon Discovery Ltd.. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.